[CAS NO. 2505001-62-5] SR18662
PRODUCTS SPECIFICATIONS [2505001-62-5]
DESCRIPTION [2505001-62-5]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 420.31 |
| Molecular Formula | C16H19Cl2N3O4S |
| SMILES | ClC1=CC(/C=C/C(NCC(N2CCN(CC2)S(C)(=O)=O)=O)=O)=CC=C1Cl |
Summary
IC50 & Target
IC50: 4.4 nM (KLF5) [1]
In Vitro
SR18662 (0-10 μM; 24-72 hours) significantly reduces growth and proliferation of CRC cells as compared to treatment with vehicle control, ML264 (HY-19994). It shows improved efficacy in reducing viability of multiple CRC cell lines
[1]
.
SR18662 (10 μM; 24-72 hours) shows a significant increase in the number of apoptotic cells at both early and late states in DLD-1 and HCT116 cells
[1]
.
SR18662 (1 μM; 72 hours) reduces the expression of cyclins (cyclins E, A2, and B1) and components of MAPK (p-Erk) and WNT signaling pathways (p-GSK3 β) in cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | CRC cells |
| Concentration: | 0-10 μM |
| Incubation Time: | 24 hours, 48 hours, 72 hours |
| Result: | Induced anti-tumor activity in colorectal cancer cell lines. |
Apoptosis Analysis [1]
| Cell Line: | DLD-1 and HCT116 cells |
| Concentration: | 10 μM |
| Incubation Time: | 24 hours, 48 hours, 72 hours |
| Result: | Increased apoptosis of colorectal cancer cell lines. |
Western Blot Analysis [1]
| Cell Line: | DLD-1 and HCT116 cells |
| Concentration: | 1 μM |
| Incubation Time: | 72 hours |
| Result: | Reduced levels of cyclins E, A2, and B1 inhibits activity of MAPK, WNT/β-catenin signaling pathways and decreases the levels of cyclins. |
In Vivo
SR18662 (intraperitoneal injection; 5-10 mg/kg; daily or twice daily; 5 days injection, days break, and 5 days) significantly reduces the growth of tumors in a mouse xenograft model
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Nude mice with DLD-1 cells [1] |
| Dosage: | 5 mg/kg; 10 mg/kg; 25 mg/kg |
| Administration: | Intraperitoneal injection; 5mg/kg daily, 5mg/kg twice a day,10 mg/kg daily, 10 mg/kg twice per day, 25mg/kg daily, and 25 mg/kg twice per day; 5 days of injections, 2 days break, and 5 days of injections |
| Result: | Caused a significant dose-dependent inhibition of xenograft growth in mice. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 125 mg/mL ( 297.40 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3792 mL | 11.8960 mL | 23.7920 mL |
| 5 mM | 0.4758 mL | 2.3792 mL | 4.7584 mL |
| 10 mM | 0.2379 mL | 1.1896 mL | 2.3792 mL |